A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.

Abstract:

:In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of HSCs with no obvious front-line strategy. We report a single institutional experience mobilizing HSCs using four different approaches in lymphoma patients. We prospectively collected mobilization outcomes on patients planned to undergo auto-HCT at Ohio State University. We report results of first mobilization attempts for all relapsed or refractory lymphoma patients between 2008 and 2014. We identified 255 lymphoma patients who underwent mobilization for planned auto-HCT. The 255 lymphoma patients underwent the following front line mobilization strategies: 95 (37%) G-CSF alone, 38 (15%) chemomobilization (G-CSF+chemotherapy), 97 (38%) preemptive day 4 plerixafor, and 25 (10%) rescue day 5 plerixafor. As expected, there were significant differences between cohorts including age, comorbidity indices, histology, and amount of prior chemotherapy. After controlling for differences between groups, the odds of collecting 2 × 106/kg HSCs on the first day of collection and 5 × 106/kg HSCs in total was the highest in the cohort undergoing chemomobilization. In conclusion, our experience highlights the effectiveness of chemomobilization.

journal_name

Bone Marrow Transplant

authors

Haverkos BM,Huang Y,Elder P,O'Donnell L,Scholl D,Whittaker B,Vasu S,Penza S,Andritsos LA,Devine SM,Jaglowski SM

doi

10.1038/bmt.2016.304

subject

Has Abstract

pub_date

2017-04-01 00:00:00

pages

561-566

issue

4

eissn

0268-3369

issn

1476-5365

pii

bmt2016304

journal_volume

52

pub_type

杂志文章
  • Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.

    abstract::During the past few years major progress has been made in the diagnosis and therapy of CMV infection after allogeneic BMT. The aim of this survey was to investigate the use of diagnostic techniques, use of prophylaxis and the therapeutic strategies among members of the EBMT. Seventy centers from 20 countries responded...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ljungman P,De Bock R,Cordonnier C,Einsele H,Engelhard D,Grundy J,Locasciulli A,Reusser P,Ribaud P

    更新日期:1993-10-01 00:00:00

  • Bone marrow transplantation in sickle cell disease: the Belgian experience.

    abstract::Twenty eight patients underwent bone marrow transplantation (BMT) for sickle cell anemia in Belgium. The patients were originating from Central Africa, were young and symptomatic. Engraftment occurred in all patients and was sustained in 25. In 3 patients, a bone marrow rejection was observed. One of these patients un...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Vermylen C,Cornu G,Ferster A,Ninane J,Sariban E

    更新日期:1993-01-01 00:00:00

  • Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.

    abstract::Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

    更新日期:1994-12-01 00:00:00

  • Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

    abstract::We retrospectively assessed the outcome and pretransplantation predictors of the outcome in 118 patients aged ≥ 50 years who received fludarabine-containing reduced-intensity allo-SCT (RIST) for B-cell ALL in the first or second CR. Eighty patients received transplants from unrelated donors. Seventy-eight patients wer...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.140

    authors: Kanamori H,Mizuta S,Kako S,Kato H,Nishiwaki S,Imai K,Shigematsu A,Nakamae H,Tanaka M,Ikegame K,Yujiri T,Fukuda T,Minagawa K,Eto T,Nagamura-Inoue T,Morishima Y,Suzuki R,Sakamaki H,Tanaka J

    更新日期:2013-11-01 00:00:00

  • Severe migratory polyarthritis following in vivo CAMPATH-1G.

    abstract::CAMPATH-1G is an IgG2b rat antihuman (CDw52) monoclonal antibody (MoAb) which is currently being used for T cell depletion in the setting of allogeneic bone marrow transplantation (BMT). In addition it elicits substantial lymphoid depletion, an effect which is being explored for remission induction in patients with ly...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Varadi G,Or R,Rund D,Orbach H,Slavin S,Nagler A

    更新日期:1995-12-01 00:00:00

  • Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.

    abstract::Few studies have addressed the incidence of graft-versus-host disease (GVHD) or survival after ABO-incompatible allogeneic peripheral blood stem cell transplantation (PBSCT). We analyzed the clinical outcome of ABO incompatibility after allogeneic PBSCT. A total of 89 consecutive adult patients with hematological dise...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704816

    authors: Kim JG,Sohn SK,Kim DH,Baek JH,Lee KB,Min WS,Kim CC,Lee MH,Lee JJ,Chung IJ,Kim HJ,Lee JW

    更新日期:2005-03-01 00:00:00

  • Cord blood banks collect units with different HLA alleles and haplotypes to volunteer donor banks: a comparative report from Swiss Blood stem cells.

    abstract::Allogeneic haematopoietic SCT is a standard therapy for many patients with haematological diseases. A major aim of public umbilical cord blood (UCB) banking is to establish an inventory with a large HLA diversity. Few studies have compared HLA diversity between UCB banks and volunteer unrelated donor (VUD) registries ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.391

    authors: Meyer-Monard S,Passweg J,Troeger C,Eberhard HP,Roosnek E,de Faveri GN,Chalandon Y,Rovo A,Kindler V,Irion O,Holzgreve W,Gratwohl A,Müller C,Tichelli A,Tiercy JM

    更新日期:2009-05-01 00:00:00

  • Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.

    abstract::HSV can cause oral lesions that exacerbate chemotherapy-related mucositis. Intravenous acyclovir is effective in preventing HSV reactivations, but expensive. Valacyclovir has good bioavailability and has not been studied for prophylaxis of HSV among PCT patients. We compared the efficacy and costs of valacyclovir in p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703354

    authors: Dignani MC,Mykietiuk A,Michelet M,Intile D,Mammana L,Desmery P,Milone G,Pavlovsky S

    更新日期:2002-02-01 00:00:00

  • Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005.

    abstract::Over more than three decades, The Anthony Nolan Trust (ANT) has provided an unrelated donor (UD) for over 4000 children and adults lacking a suitable family member donor, and has remained at the forefront of developments in haematopoietic stem cell transplantation (HSCT) and bone marrow register management. These thre...

    journal_title:Bone marrow transplantation

    pub_type:

    doi:10.1038/sj.bmt.1705365

    authors: Duarte RF,Pamphilon D,Cornish J,Shaw BE,Samson D,Craddock C,Marks D,Mufti GJ,Powles RL,Apperley JF,Madrigal JA,Goldman JM

    更新日期:2006-05-01 00:00:00

  • Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.

    abstract::Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34+ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702378

    authors: Limat S,Woronoff-Lemsi MC,Deconinck E,Racadot E,Jacquet M,Herve P,Cahn JY

    更新日期:2000-05-01 00:00:00

  • Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients.

    abstract::We conducted an observational study to assess the etiology, clinical features and outcomes of bloodstream infection (BSI) in 172 hematopoietic SCT (HCST) recipients. One hundred episodes of BSI in the pre-engraftment period (early onset) were compared with 89 episodes in the post-engraftment phase (late onset). More p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.37

    authors: Gudiol C,Garcia-Vidal C,Arnan M,Sánchez-Ortega I,Patiño B,Duarte R,Carratalà J

    更新日期:2014-06-01 00:00:00

  • Bone marrow steady-state CD34+/CD71- cell content is a predictive value of rG-CSF-mobilized CD34+ cells.

    abstract::Thirty-four patients diagnosed with breast cancer were included in a prospective study evaluating the bone marrow (BM) CD34+/CD71- cell content, as a predictive parameter of the CD34+ cell mobilization after rG-CSF administration. Analysis of the concentration of medullary CD34+/CD71- cells before priming schedules wa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701227

    authors: Osma MM,Ortuño F,de Arriba F,Lozano ML,Heras I,Moraleda JM,Vicente V

    更新日期:1998-05-01 00:00:00

  • Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

    abstract::Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.74

    authors: Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

    更新日期:2015-07-01 00:00:00

  • Delayed or delayed sequential bone marrow transplantation: relevance for acute graft-versus-host disease prevention after major H2 incompatible transplantation.

    abstract::During this study, BalB/C mice were used as recipients and C57 bl/6 mice as donors. Recipients were given 800 cGys of total body irradiation (TBI) on day 0. Transplantation was carried out as follows: group (1): TBI on day 0; group (2): TBI on day 0 and transplantation on day +1; group (3): TBI on day 0 and transplant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704877

    authors: Mabed M,Maroof S,Zalta K,El-Awadee M

    更新日期:2005-04-01 00:00:00

  • Assessing the potential role of photopheresis in hematopoietic stem cell transplant.

    abstract::The First International Symposium on Photopheresis in Hematopoietic Stem Cell Transplantation was held in Vienna, Austria with an educational grant from Therakos Inc. from 25 May to 27 May 2005. Three general issues were addressed: (1) pathophysiology of graft-versus-host disease (GvHD), (2) induction of immune tolera...

    journal_title:Bone marrow transplantation

    pub_type:

    doi:10.1038/sj.bmt.1705440

    authors: Greinix HT,Socié G,Bacigalupo A,Holler E,Edinger MG,Apperley JF,Schwarz T,Ullrich SE,Albert ML,Knobler RM,Peritt D,Ferrara JL

    更新日期:2006-08-01 00:00:00

  • Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.

    abstract::Certain leukemias have a high relapse risk even after allo-SCT, and GVHD prophylaxis with calcineurin inhibitors (CNIs) may interfere with a possible GVL effect. Therefore, we replaced CYA by sirolimus in patients with high relapse risk. In contrast to CNIs, sirolimus promotes the generation of regulatory T-cells and ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2008.377

    authors: Schleuning M,Judith D,Jedlickova Z,Stübig T,Heshmat M,Baurmann H,Schwerdtfeger R

    更新日期:2009-05-01 00:00:00

  • A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation.

    abstract::A fatal case of EBV-associated lymphoproliferative disorder arising after a CD34-selected autologous peripheral blood stem cell transplant is reported in a patient with multiple myeloma in first plateau phase. It is suggested that this is likely to be a consequence of the accessory cell depletion associated with the C...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701335

    authors: Peniket AJ,Perry AR,Williams CD,MacMillan A,Watts MJ,Isaacson PG,Goldstone AH,Linch DC

    更新日期:1998-08-01 00:00:00

  • Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract::To analyze the incidence, characteristics and risk factors of hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning (allo-RIC), we conducted a retrospective study in three Spanish centers. We analyzed 452 consecutive patients receiving allo-RIC. Of these, 92 patient...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2012.25

    authors: Barba P,Martino R,Perez-Simón JA,Fernández-Avilés F,Piñana JL,Valcárcel D,Campos-Varela I,Lopez-Anglada L,Rovira M,Novelli S,Lopez-Corral L,Carreras E,Sierra J

    更新日期:2012-10-01 00:00:00

  • Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

    abstract::Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0857-x

    authors: Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

    更新日期:2020-10-01 00:00:00

  • Adhesion molecules on peripheral blood-derived CD34+ cells: effects of cryopreservation and short-term ex vivo incubation with serum and cytokines.

    abstract::The homing of hematopoietic precursor cells (HPC) within the bone marrow is most likely to be mediated by specific adhesion via surface receptors to cellular and extracellular matrix (ECM) components and to be regulated by cytokines. We investigated the effects of serum and cytokines on the expression of adhesion mole...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701484

    authors: Koenigsmann MP,Koenigsmann M,Notter M,Neuloh M,Mücke C,Thiel E,Berdel WE

    更新日期:1998-12-01 00:00:00

  • Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).

    abstract::Allogeneic BMT for patients with acute myeloid leukemia (AML) is presently a reference therapy. The indications for this therapy mainly rely upon prognostic factors, and their importance is constantly reassessed. To examine the impact of time from diagnosis to transplant on survival and leukemia-free survival (LFS), w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700761

    authors: Jourdan E,Maraninchi D,Reiffers J,Gluckman E,Rio B,Jouet JP,Michallet M,Molina L,Archimbaud E,Harousseau JL,Ifrah N,Attal M,Guilhot F,Kuentz M,Guyotat D,Pico JL,Dauriac C,Legros M,Dreyfus F,Bordigoni P,Leblond V,

    更新日期:1997-05-01 00:00:00

  • Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.

    abstract::Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and durable remission. Study patients (n=30) had unfavorable first remission cytogenetics, progression from myelodyspl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.295

    authors: Stein AS,O'Donnell MR,Synold TW,Dagis AC,Tsirunyan A,Nademanee AP,Parker PM,Pullarkat VA,Snyder DS,Spielberger RT,Wong JY,Alvarnas JC,Thomas SH,Forman SJ

    更新日期:2011-09-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

    abstract::The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.173

    authors: Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

    更新日期:2014-02-01 00:00:00

  • Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.

    abstract::We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2009.316

    authors: Kimura S,Oshima K,Okuda S,Sato K,Sato M,Terasako K,Nakasone H,Kako S,Yamazaki R,Tanaka Y,Tanihara A,Higuchi T,Nishida J,Kanda Y

    更新日期:2010-06-01 00:00:00

  • Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease.

    abstract::Pentaglobin is a commercial immunoglobulin preparation which is enriched specifically for IgM and also contains antibodies that are capable of neutralizing endotoxins. Its potential use in treating patients with acute graft-versus-host disease (GVHD) was studied in a phase I/II study. Pentaglobin was administered at a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Klingemann HG,Barnett MJ,Reece DE,Shepherd JD,Phillips GL

    更新日期:1990-09-01 00:00:00

  • Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor.

    abstract::We describe a healthy peripheral blood stem cell (PBSC) donor who developed a cutaneous reaction, erythema exsudativum multiforme, during the administration of granulocyte colony-stimulating factor (G-CSF) for mobilization. The cutaneous lesions were located on his hips, apart from the site of G-CSF injection. Treatme...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702501

    authors: Mori T,Sato N,Watanabe R,Okamoto S,Ikeda Y

    更新日期:2000-07-01 00:00:00

  • Pregnancy outcome following hematopoietic cell transplantation for thalassemia major.

    abstract::The aim of this study was to investigate the methods of conception and delivery, as well as the course and outcome of 42 pregnancies occurring in 15 female patients (27 pregnancies) and partners of 8 male patients (15 pregnancies) with β-thalassemia major who were successfully treated with allogeneic hematopoietic cel...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2016.287

    authors: Santarone S,Natale A,Olioso P,Onofrillo D,D'Incecco C,Parruti G,Di Bartolomeo P

    更新日期:2017-03-01 00:00:00

  • Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.

    abstract::To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD proph...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703916

    authors: Verma A,Devine S,Morrow M,Chen YH,Mihalov M,Peace D,Stock W,Pursell K,Wickrema A,Yassine M,Jessop E,van Besien K

    更新日期:2003-05-01 00:00:00

  • Immunological questions on hematopoietic stem cell transplantation for multiple sclerosis.

    abstract::Multiple sclerosis (MS) is considered an inflammatory autoimmune disorder. Approved immunotherapies are only moderately effective in reducing disease exacerbations and brain inflammation in a subset of patients. Autologous hematopoietic stem cell transplantation (HSCT) has emerged in recent years as the first opportun...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1704096

    authors: Muraro PA,Martin R

    更新日期:2003-08-01 00:00:00

  • Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas.

    abstract::We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas (N = 143). Blood cells were mobilised with filgrastim given for 4-5 days and collected after a median of 2 (range, 1-2) aph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-017-0047-7

    authors: Kardduss-Urueta A,Gale RP,Gutierrez-Aguirre CH,Herrera-Rojas MA,Murrieta-Álvarez I,Perez-Fontalvo R,Ruiz-Delgado GJ,Ruiz-Rojas G,Jaimovich G,Feldman L,Labastida-Mercado N,Endara A,Castro M,Galindo-Becerra S,Cardona-Molina MA

    更新日期:2018-04-01 00:00:00